Skip to main content
Top
Published in:

26-07-2023 | Post Traumatic Stress Disorder | BRIEF REPORT

Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations

Authors: Braeden A. Mair, BSc, Jason G. E. Zelt, MD, PhD, Kirabo Nekesa, BSc, Zacharie Saint-Georges, BSc, Katie Dinelle, MSc, Myriam Adi, BSc, Simon Robinson, PhD, Lisa M. Mielniczuk, MD, Jakov Shlik, MD, PhD, Rob S. Beanlands, MD, Robert A. deKemp, PhD, Benjamin H. Rotstein, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2023

Login to get access

Abstract

Background

Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.

Methods

Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.

Results

The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.

Conclusions

Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.
Appendix
Available only for authorised users
Literature
4.
Metadata
Title
Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations
Authors
Braeden A. Mair, BSc
Jason G. E. Zelt, MD, PhD
Kirabo Nekesa, BSc
Zacharie Saint-Georges, BSc
Katie Dinelle, MSc
Myriam Adi, BSc
Simon Robinson, PhD
Lisa M. Mielniczuk, MD
Jakov Shlik, MD, PhD
Rob S. Beanlands, MD
Robert A. deKemp, PhD
Benjamin H. Rotstein, PhD
Publication date
26-07-2023
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 5/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-023-03338-9

Other articles of this Issue 5/2023

Journal of Nuclear Cardiology 5/2023 Go to the issue
Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine